rs11571769

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_000059.4(BRCA2):​c.8851G>A​(p.Ala2951Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00692 in 1,613,810 control chromosomes in the GnomAD database, including 134 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.0084 ( 38 hom., cov: 33)
Exomes 𝑓: 0.0068 ( 96 hom. )

Consequence

BRCA2
NM_000059.4 missense

Scores

6
3
6

Clinical Significance

Benign reviewed by expert panel P:1B:44O:1

Conservation

PhyloP100: 7.91
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.005076319).
BP6
Variant 13-32379413-G-A is Benign according to our data. Variant chr13-32379413-G-A is described in ClinVar as [Benign]. Clinvar id is 41570.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr13-32379413-G-A is described in Lovd as [Benign]. Variant chr13-32379413-G-A is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.00841 (1281/152290) while in subpopulation AMR AF= 0.0508 (777/15300). AF 95% confidence interval is 0.0478. There are 38 homozygotes in gnomad4. There are 724 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 38 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
BRCA2NM_000059.4 linkuse as main transcriptc.8851G>A p.Ala2951Thr missense_variant 22/27 ENST00000380152.8 NP_000050.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
BRCA2ENST00000380152.8 linkuse as main transcriptc.8851G>A p.Ala2951Thr missense_variant 22/275 NM_000059.4 ENSP00000369497 A2

Frequencies

GnomAD3 genomes
AF:
0.00835
AC:
1270
AN:
152172
Hom.:
34
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00123
Gnomad AMI
AF:
0.00110
Gnomad AMR
AF:
0.0502
Gnomad ASJ
AF:
0.00144
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.0141
Gnomad FIN
AF:
0.000754
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.00512
Gnomad OTH
AF:
0.0100
GnomAD3 exomes
AF:
0.00955
AC:
2395
AN:
250796
Hom.:
41
AF XY:
0.00886
AC XY:
1201
AN XY:
135576
show subpopulations
Gnomad AFR exome
AF:
0.00123
Gnomad AMR exome
AF:
0.0378
Gnomad ASJ exome
AF:
0.00159
Gnomad EAS exome
AF:
0.000163
Gnomad SAS exome
AF:
0.0142
Gnomad FIN exome
AF:
0.000786
Gnomad NFE exome
AF:
0.00493
Gnomad OTH exome
AF:
0.00670
GnomAD4 exome
AF:
0.00677
AC:
9893
AN:
1461520
Hom.:
96
Cov.:
31
AF XY:
0.00681
AC XY:
4951
AN XY:
727048
show subpopulations
Gnomad4 AFR exome
AF:
0.00114
Gnomad4 AMR exome
AF:
0.0392
Gnomad4 ASJ exome
AF:
0.00138
Gnomad4 EAS exome
AF:
0.0000756
Gnomad4 SAS exome
AF:
0.0146
Gnomad4 FIN exome
AF:
0.000543
Gnomad4 NFE exome
AF:
0.00574
Gnomad4 OTH exome
AF:
0.00620
GnomAD4 genome
AF:
0.00841
AC:
1281
AN:
152290
Hom.:
38
Cov.:
33
AF XY:
0.00972
AC XY:
724
AN XY:
74480
show subpopulations
Gnomad4 AFR
AF:
0.00123
Gnomad4 AMR
AF:
0.0508
Gnomad4 ASJ
AF:
0.00144
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.0141
Gnomad4 FIN
AF:
0.000754
Gnomad4 NFE
AF:
0.00513
Gnomad4 OTH
AF:
0.00992
Alfa
AF:
0.00468
Hom.:
3
Bravo
AF:
0.00992
TwinsUK
AF:
0.00566
AC:
21
ALSPAC
AF:
0.00649
AC:
25
ESP6500AA
AF:
0.00182
AC:
8
ESP6500EA
AF:
0.00570
AC:
49
ExAC
AF:
0.00782
AC:
949
Asia WGS
AF:
0.00693
AC:
24
AN:
3478
EpiCase
AF:
0.00491
EpiControl
AF:
0.00563

ClinVar

Significance: Benign
Submissions summary: Pathogenic:1Benign:44Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 2 Benign:13
Benign, reviewed by expert panelcurationEvidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)Sep 28, 2016Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.036 (Admixed American/Latino), 0.0215 (South Asian), derived from 1000 genomes (2013-05-02). -
Benign, no assertion criteria providedclinical testingSharing Clinical Reports Project (SCRP)Mar 14, 2011- -
Benign, criteria provided, single submitterclinical testingMichigan Medical Genetics Laboratories, University of MichiganNov 03, 2014- -
Likely benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 29, 2018This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
Benign, criteria provided, single submitterclinical testingPathway GenomicsOct 30, 2014- -
Benign, criteria provided, single submitterclinical testingKCCC/NGS Laboratory, Kuwait Cancer Control CenterJul 07, 2023- -
Benign, criteria provided, single submitterliterature onlyCounsylJan 02, 2014- -
Benign, no assertion criteria providedclinical testingBreast Cancer Information Core (BIC) (BRCA2)May 29, 2002- -
Benign, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
Likely benign, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsDec 07, 2015- -
Benign, criteria provided, single submitterclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical CenterSep 21, 2015- -
Benign, criteria provided, single submitterclinical testingGenome Diagnostics Laboratory, University Medical Center UtrechtOct 09, 2014- -
Benign, criteria provided, single submitterclinical testingGenetics and Molecular Pathology, SA PathologyMay 25, 2022The BRCA2 c.8851G>A variant is classified as Benign -
not specified Benign:9Other:1
Benign, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalAug 15, 2023- -
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesOct 31, 2016- -
not provided, no classification providedreference populationITMISep 19, 2013- -
Benign, no assertion criteria providedclinical testingLaboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)-- -
Benign, criteria provided, single submitterclinical testingCancer Genetics and Genomics Laboratory, British Columbia Cancer AgencyApr 18, 2017- -
Benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Benign, no assertion criteria providedclinical testingClinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute-- -
Benign, criteria provided, single submitterclinical testingGeneDxOct 02, 2013This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineMar 28, 2016Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: ExAC: 3.5% (402/11526) Latino chromosomes -
Benign, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Jul 30, 2015- -
not provided Benign:6
Benign, criteria provided, single submitterclinical testingCenter for Pediatric Genomic Medicine, Children's Mercy Hospital and ClinicsSep 28, 2016- -
Benign, no assertion criteria providedresearchBiesecker Lab/Clinical Genomics Section, National Institutes of HealthJul 13, 2012- -
Likely benign, no assertion criteria providedclinical testingMayo Clinic Laboratories, Mayo ClinicMar 30, 2017- -
Benign, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 27, 2023- -
Benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenNov 01, 2024BRCA2: PM5, BP4, BS1, BS2 -
Hereditary cancer-predisposing syndrome Benign:5
Benign, criteria provided, single submitterclinical testingAmbry GeneticsAug 01, 2014This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Benign, criteria provided, single submittercurationSema4, Sema4Mar 20, 2020- -
Benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthDec 30, 2014- -
Benign, criteria provided, single submitterclinical testingVantari GeneticsJan 06, 2016- -
Benign, no assertion criteria providedclinical testingTrue Health DiagnosticsSep 13, 2017- -
Hereditary breast ovarian cancer syndrome Benign:5
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpFeb 04, 2014- -
Benign, criteria provided, single submitterresearchGenetics Program, Instituto Nacional de CancerNov 01, 2021- -
Benign, criteria provided, single submitterclinical testingNational Health Laboratory Service, Universitas Academic Hospital and University of the Free StateNov 16, 2021- -
Benign, criteria provided, single submitterclinical testingGenomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of PhiladelphiaOct 20, 2015- -
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
Malignant tumor of breast Benign:2
Benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-The p.Ala2951Thr variant has been reported in our laboratory as well as in the literature in 36/5864 (0.006 frequency) proband chromosomes and in 1/1018 control chromosomes (0.001 frequency) (Bergthorsson_2001_11389159, Borg_2010_20104584, Saxena_2006_17018160, Lin_2003_12815053, Spitzer_2000_10699917, Serova-Sinilnikova_1997_9150172, Weber_2006_16685647, Wagner_1999_9971877, Waddell_2008_18497862). It is listed in dbSNP database (ID#:rs11571769) but no frequency information was provided, and so the prevalence of this variant in the general population is not known. The p.Ala2951 residue is conserved across vertebrate species, and computational analyses (PolyPhen2, SIFT, AlignGVGD) suggest that the p.Ala2951Thr variant may impact the protein. However, this information is not predictive enough to assume pathogenicity. In one study, this variant did not co-segregate with cancer in three families, and its frequency in 4680 clinical samples was similar to that of the control population (Deffenbaugh_2002_12215251). Notably, this variant has been identified in the UMD database in a total of 15 individuals who had a second pathogenic variant (9 with BRCA2 mutations and 6 with BRCA1) and associated with a breast or ovarian cancer phenotype, increasing the likelihood that the p.Ala2951Thr variant does not have clinical significance. In addition, Myriad calls this variant as a polymorphism. In summary, based on the above information this variant is classified as benign. -
Benign, no assertion criteria providedclinical testingCenter of Medical Genetics and Primary Health Care-- -
Ovarian cancer Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingLaboratory of Molecular Epidemiology of Birth Defects, West China Second University Hospital, Sichuan UniversityJan 01, 2022- -
Breast and/or ovarian cancer Benign:1
Benign, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioJan 04, 2016- -
Fanconi anemia complementation group D1 Benign:1
Likely benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 29, 2018This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
BRCA2-related cancer predisposition Benign:1
Benign, criteria provided, single submitterclinical testingAll of Us Research Program, National Institutes of HealthSep 27, 2024- -
Familial cancer of breast Benign:1
Benign, criteria provided, single submitterclinical testingBaylor GeneticsFeb 23, 2017- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.14
T
BayesDel_noAF
Uncertain
0.060
CADD
Pathogenic
26
DANN
Pathogenic
1.0
Eigen
Pathogenic
0.83
Eigen_PC
Pathogenic
0.77
FATHMM_MKL
Pathogenic
0.98
D
MetaRNN
Benign
0.0051
T;T
MetaSVM
Uncertain
-0.23
T
MutationTaster
Benign
1.0
D;D
PrimateAI
Benign
0.44
T
PROVEAN
Benign
-1.2
N;N
REVEL
Uncertain
0.40
Sift
Pathogenic
0.0
D;D
Sift4G
Pathogenic
0.0
D;D
Vest4
0.51
MVP
0.89
MPC
0.16
ClinPred
0.020
T
GERP RS
5.6
gMVP
0.33

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs11571769; hg19: chr13-32953550; COSMIC: COSV66463542; COSMIC: COSV66463542; API